Mitxelena, A. and Areses, M. (2022) “Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence”, Osagaiz: osasun-zientzien aldizkaria, 6(1). Available at: https://aldizkariak.ueu.eus/index.php/osagaiz/article/view/362 (Accessed: 11 November 2026).